Absolutely sensational work by SI and the Mesoblast Team in achieving the FDA approved intermediate-size expanded access protocol to treat approximately 50 children or adolescents with MIS-C associated with COVID-19 using Mesoblast Stem Cell product Remestemcel-L.
This is further affirmation that the FDA are now on board and committed to moving through the various stages and path to commercial approval of MSB Stem Cell products and IMO, this is a prelude to a Phase 2/3 Trial similar to ARDS COVID for Rem L.
Looking forward to the first of many announcements in July.
GLTAH
Absolutely sensational work by SI and the Mesoblast Team in...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |